Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:52:03.888Z.
Calculation as of: 2026-10-06T18:52:03.888Z.
Quote observation: 2026-10-06T18:50:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
LENZ Therapeutics, Inc.
Market Cap
$119.34M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $119.34M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.21M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.28M | N/A |
| BGM Group Ltd. (BGM)vs › | $117.61M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.61M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.52M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.55M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
